Frazier Life Sciences Management L.P. Grows Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Frazier Life Sciences Management L.P. lifted its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 22.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 583,327 shares of the company’s stock after buying an additional 106,000 shares during the quarter. Frazier Life Sciences Management L.P. owned approximately 1.67% of Oruka Therapeutics worth $11,311,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new stake in shares of Oruka Therapeutics in the 4th quarter worth about $54,000. AlphaCentric Advisors LLC purchased a new stake in shares of Oruka Therapeutics in the 4th quarter worth about $119,000. China Universal Asset Management Co. Ltd. purchased a new stake in Oruka Therapeutics during the 4th quarter valued at about $144,000. Squarepoint Ops LLC purchased a new stake in Oruka Therapeutics during the 4th quarter valued at about $236,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Oruka Therapeutics during the 4th quarter valued at about $303,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Performance

ORKA opened at $10.62 on Wednesday. The stock has a market capitalization of $397.62 million, a P/E ratio of -1.70 and a beta of 0.25. The company’s 50-day simple moving average is $9.83 and its two-hundred day simple moving average is $14.54. Oruka Therapeutics, Inc. has a 52-week low of $5.49 and a 52-week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. Research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on ORKA. Wedbush reissued an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 15th. Wolfe Research began coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Buy” and an average target price of $39.86.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.